MedTrace Logo

Type 2 Diabetes and Binge Eating Disorder (BED)

NCT06325670 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-02-09

No results posted yet for this study

Summary

The goal of this research project is to improve the treatment of individuals living with both type 2 diabetes (T2D) and Binge Eating Disorder (BED). The research hypothesizes that BED treatment will not only improve BED symptoms but also improve T2D severity and associated cardiovascular risk factors. The research involves a multidisciplinary team, including experts in endocrinology, psychology, and eating disorders.

The main questions it aims to answer are:

* Does treatment for Binge Eating Disorder lead to improvements in BED symptoms?
* Does treatment for Binge Eating Disorder lead to improvements in T2D severity and associated cardiovascular risk factors?

Participants will undergo a comprehensive treatment program targeting both BED and T2D. This program will include psychotherapy sessions focusing on cognitive-behavioral techniques to address binge eating behavior.

Researchers will compare participants' outcomes before and after the treatment program to assess changes in BED symptoms, T2D severity, and associated cardiovascular risk factors.

Conditions

  • Diabetes Mellitus, Type 2
  • Binge-Eating Disorder

Interventions

BEHAVIORAL

BED treatment

A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.

OTHER

Waitlist

A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.

Sponsors & Collaborators

  • Jascha Fonden

    collaborator OTHER

  • Independent Research Fund Denmark

    collaborator INDUSTRY

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Pernille Fiil Nybo, cand.psych. · University og Southern Denmark, SDU

  • Jakob Linnet, Dr.med., cand.psych. · Occupational- and Environmental Clinic, OUH

  • Michael Roeder, Dr.med. · Steno Diabetes Center Odense

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2025-04-02
Completion
2026-02-03

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06325670 on ClinicalTrials.gov